ArticleJournal of microbiology and biotechnology2025
Portable RT-LAMP Platform for Rapid Point-of-Care Detection for SFTSV.
Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the Gut-Brain Axis Through Insulin-like Growth Factors: Therapeutic Implications and Future Directions.Journal of molecular neuroscience : MN · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a tick-borne pathogen associated with high mortality, particularly among the elderly, and poses a significant public health threat in East Asia's rural areas. Improved diagnostic approaches are crucial for effective disease management in resource-limited settings. In this study, we developed a portable Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) platform for rapid and accurate SFTSV detection. Primers targeting the conserved L gene were designed using 158 sequences collected between 2019 and 2023, and a multiplex assay incorporating the β-actin gene as an internal control to verify amplification efficiency in alignment with clinical performance requirements. We assessed the assay's sensitivity and specificity, ultimately establishing the RT-LAMP platform in a portable, clinical-grade device. The RT-LAMP assay achieved a detection limit of 500 RNA copies per reaction and provided results within 20 min. It demonstrated high specificity without cross-reactivity with other pathogens. Performance comparisons with commercial qRT-PCR kits using clinical specimens confirmed the RT-LAMP platform's reliability. The newly developed RT-LAMP platform is a rapid, accurate, and cost-effective diagnostic tool for SFTSV with strong potential for point-of-care testing (POCT). Its portability and ease of use make it ideal for application in resource-constrained environments, thereby enhancing SFTSV surveillance and improving public health outcomes in affected regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.